Epirubicin vs epirubicin plus cisplatin vs epirubicin plus lonidamine vs epirubicin plus cisplatin plus lonidamine as first line treatment in advanced breast cancer (BC) patients. A randomized multicenter phase III trial with a factorial design.

被引：0
|
作者：
Dogliotti, L
Berruti, A
Bitossi, R
Gorzegno, G
Bottini, A
Alquati, P
De Matteis, A
Nuzzo, F
Giardina, B
Danese, S
De Lena, M
Lorusso, V
Farris, A
Sarobba, MG
DeFabiani, E
Spanu, G
Bonazzi, G
Castiglione, F
Bumma, C
Moro, G
Galletto, L
机构：
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E28
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [1] Weekly epirubicin plus lonidamine in advanced breast carcinoma
    Cecilia Nisticò
    Carlo Garufi
    Michele Milella
    Anna Maria D'Ottavio
    Angela Vaccaro
    Alessandra Fabi
    Edmondo Terzoli
    Breast Cancer Research and Treatment, 1999, 56 (3) : 231 - 235
  • [2] Weekly epirubicin plus lonidamine in advanced breast carcinoma
    Nisticò, C
    Garufi, C
    Milella, M
    D'Ottavio, AM
    Vaccaro, A
    Fabi, A
    Terzoli, E
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 56 (03) : 233 - 237
  • [3] Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
    E Baldini
    T Prochilo
    B Salvadori
    A Bolognesi
    D Aldrighetti
    M Venturini
    R Rosso
    F Carnino
    L Gallo
    P Giannessi
    P F Conte
    C Orlandini
    P Bruzzi
    British Journal of Cancer, 2004, 91 : 45 - 49
  • [4] Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
    Baldini, E
    Prochilo, T
    Salvadori, B
    Bolognesi, A
    Aldrighetti, D
    Venturini, M
    Rosso, R
    Carnino, F
    Gallo, L
    Giannessi, P
    Conte, PF
    Orlandini, C
    Bruzzi, P
    BRITISH JOURNAL OF CANCER, 2004, 91 (01) : 45 - 49
  • [5] Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel: focus on cardiac safety.
    Baldini, E
    Salvadori, B
    Prochilo, T
    Bolognesi, A
    Aldrighetti, D
    Venturini, M
    Rosso, R
    Carnino, F
    Visentini, L
    Gallo, L
    Mammoliti, S
    Giannessi, PG
    Di Marsico, R
    Bruzzi, P
    Conte, PF
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S89 - S89
  • [6] Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study
    Gardin, G
    Barone, C
    Nascimben, O
    Ianniello, G
    Sturba, F
    Contu, A
    Pronzato, P
    Rosso, R
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 176 - 177
  • [7] CISPLATIN PLUS EPIRUBICIN AND ETOPOSIDE FOLLOWED BY IRRADIATION PLUS LONIDAMINE IN STAGE-III NONSMALL CELL LUNG-CANCER
    FILIPAZZI, V
    CATTANEO, MT
    RHO, B
    FRONTINI, L
    DADDA, D
    ISA, L
    SCAPATICCI, R
    LEGNANI, W
    CALZAVARA, MP
    BERNI, F
    PIAZZA, E
    ONCOLOGY, 1993, 50 (01) : 10 - 13
  • [8] Cisplatin plus epirubicin plus paclitaxel weekly regimen in advanced breast cancer: A phase I study
    Frasci, G
    Manzione, L
    Comella, P
    D'Aiuto, G
    Capasso, I
    Carteni, G
    Thomas, R
    Pacilio, C
    Apicella, A
    Gravina, A
    Guida, T
    Di Bonito, M
    Piccolo, S
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 15 - 16
  • [9] Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide vs 5-FU + epirubicin plus cyclophosphamide in operable breast cancer
    Roche, H.
    Penault-Llorca, F.
    Berton, Rigaud D.
    Tubiana, Mathieu N.
    Ferrero, J. M.
    Coudert, B.
    Mousseau, M.
    Monnier, A.
    Orfuevre, H.
    Audhuy, B.
    Rotarski, M.
    Homokos, H.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S225 - S225
  • [10] Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
    Bonneterre, J
    Dieras, V
    Tubiana-Hulin, M
    Bougnoux, P
    Bonneterre, ME
    Delozier, T
    Mayer, F
    Culine, S
    Dohoulou, N
    Bendahmane, B
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1466 - 1471
12345